Progress in the therapeutic inhibition of Cdc42 signalling.
View / Open Files
Publication Date
2021-06-30Journal Title
Biochem Soc Trans
ISSN
0300-5127
Publisher
Portland Press Ltd.
Volume
49
Issue
3
Pages
1443-1456
Language
eng
Type
Article
This Version
AM
Physical Medium
Print
Metadata
Show full item recordCitation
Murphy, N., Mott, H., & Owen, D. (2021). Progress in the therapeutic inhibition of Cdc42 signalling.. Biochem Soc Trans, 49 (3), 1443-1456. https://doi.org/10.1042/BST20210112
Abstract
Cdc42 is a member of the Rho family of small GTPases and a key regulator of the actin cytoskeleton, controlling cell motility, polarity and cell cycle progression. It signals downstream of the master regulator Ras and is essential for cell transformation by this potent oncogene. Overexpression of Cdc42 is observed in several cancers, where it is linked to poor prognosis. As a regulator of both cell architecture and motility, deregulation of Cdc42 is also linked to tumour metastasis. Like Ras, Cdc42 and other components of the signalling pathways it controls represent important potential targets for cancer therapeutics. In this review, we consider the progress that has been made targeting Cdc42, its regulators and effectors, including new modalities and new approaches to inhibition. Strategies under consideration include inhibition of lipid modification, modulation of Cdc42-GEF, Cdc42-GDI and Cdc42-effector interactions, and direct inhibition of downstream effectors.
Sponsorship
BBSRC (1947741)
Biotechnology and Biological Sciences Research Council (BB/M011194/1)
Identifiers
External DOI: https://doi.org/10.1042/BST20210112
This record's URL: https://www.repository.cam.ac.uk/handle/1810/322359
Rights
All rights reserved
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.